[12] Patent
[11] Patent No.:GC0009392  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141779
Date of the Decision to Grant the Patent:17/Dec/2018

[21] Application No.:GC 2013-25344

[22] Filing Date:10/9/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
10/9/2012
13/3/2013
61/699,122
61/780,540

[72] Inventors:1- Christopher F. BENDER،2- Xin JIANG،3- Eric ANDERSON،4- Melean VISNICK

[73] Owner: Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648, USA

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: A61K 31/56; C07C 255/47; C07D 207/08, 211/46, 213/75, 295/205, 305/08; C07J 63/00 (2006.01)

[56] Cited Documents:

-WO 2009/129545 A1 (REATA PHARMACEUTICALS INC [US]; ANDERSON ERIC [US]; JIANG XIN [US]; LI) 22 October 2009
-JP 2001 240573 A (MEIJI SEIKA KAISHA.LTD .• JAPAN) 4 September 2001
-WO 2012/125488 A1 (REATA PHARMACEUTICALS INC [US]; ANDERSON ERIC [US]; JIANG XIN [US]; VI) 20 September 2012
 
Examiner: PH. Mohammad S. AlMousa

[54] C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF
[57] Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: (I),wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.
No. of claims: 55


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.